Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-26-170345
Filing Date
2026-04-22
Accepted
2026-04-22 16:05:02
Documents
2
Period of Report
2026-04-17

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1787
2 EX-24.1 ck0001778016-ex24_1.htm EX-24.1 22243
  Complete submission text file 0001193125-26-170345.txt   25558
Mailing Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850
Business Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850 (301) 670 2800
NovaBridge Biosciences (Issuer) CIK: 0001778016 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O NOVABRIDGE BIOSCIENCES 2440 RESEARCH BOULEVARD, SUITE 400 ROCKVILLE MD 20850
Business Address
Hagler Mark Arnold (Reporting) CIK: 0002126029 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39173 | Film No.: 26883706